Sherlock: Leveraging CRISPR, synthetic biology for diagnostics

How Sherlock is leveraging CRISPR gene editing, synthetic biology to rapidly and accurately detect disease

By taking advantage of two hot technologies, Sherlock is developing a pair of molecular diagnostics that can be used alone or together to rapidly and accurately detect disease in a wide variety of applications.

Sherlock Biosciences Inc. launched in March with $35 million in funding and exclusive licenses to a CRISPR-based diagnostic from Feng Zhang's lab at the Broad Institute of MIT and Harvard and a synthetic biology platform from Jim Collins' team at Harvard University, both pioneers in their fields.

Zhang, a core institute member at Broad and the chair of Sherlock’s advisory board, and Collins, a professor of biomedical engineering at MIT

Read the full 1027 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers